Keratinocyte Carcinomas in Immunocompromised Patients Are Reduced After Administration of the Nonavalent Human Papillomavirus Vaccine

Nichols, Anna; Nahm, William J.; Rabinovitz, Harold; Ioannides, Tim

doi:10.36849/jdd.6536

Cited by 6 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, there are reports that HPV vaccines could offer cross-protection against HPV strains beyond the specific subtypes the administered vaccine targets [ 71 , 72 ]. The 9vHPV vaccine, incorporating antigens from the α-HPV genera, has the potential to elicit humoral immunity to β-HPV, given the shared expression of L1 and L2 capsid proteins [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Unveiling the Therapeutic Horizon: HPV Vaccines and Their Impact on Cutaneous Diseases—A Comprehensive Review

Șandru,

Radu,

Petca

et al. 2024

Vaccines

View full text Add to dashboard Cite

Human papillomavirus (HPV) encompasses a diverse array of viruses, comprising approximately 200 serotypes that affect humans. While the majority of HPV strains are associated with benign skin or mucous membrane growths, a subset is implicated in severe health conditions, such as cervical, anal, vulvar, and vaginal cancers. Despite the established effectiveness of HPV vaccines in preventing cervical and anal carcinomas in particular, their therapeutic potential in addressing cutaneous diseases linked to diverse HPV strains remains an intriguing area of investigation. This narrative review critically examines the existing literature to assess the viability of HPV immunization as a therapeutic intervention for prevalent cutaneous conditions. These include genital and extragenital cutaneous warts, epidermodysplasia verruciformis, and keratinocyte carcinomas. The findings suggest a promising dual role for HPV vaccines in preventing and treating dermatologic conditions while emphasizing future research directions, including the immunization perspective against β-HPVs. Moreover, the presence of conflicting study outcomes underscores the imperative for larger-scale, randomized trials with well-matched control groups to validate the efficacy of HPV immunization in the dermatologic context. This review contributes valuable insights into the evolving landscape of HPV-vaccine applications in the field of dermatology.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Patient 1 witnessed an 88% reduction in new keratinocyte carcinomas per year, including an 87% decrease in SCCs and complete postinjection prevention of BCCs. Similarly, Patient 2 experienced a 63% reduction in the yearly incidence of keratinocyte carcinomas, with a 30% decrease in SCCs and complete prevention of BCCs [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

Unveiling the Therapeutic Horizon: HPV Vaccines and Their Impact on Cutaneous Diseases—A Comprehensive Review

Șandru,

Radu,

Petca

et al. 2024

Vaccines

View full text Add to dashboard Cite

show abstract

“…For example, the quadrivalent HPV vaccine has been recently shown to reduce HPV infections and genital warts in HIV women ( 55 , 56 ). There is also recent data demonstrating that in immunosuppressed individuals (HIV-infected, with a SOT history, including KT, or being on medications that suppress the immune system), HPV vaccination was associated with the development of less CIN2 + precancerous lesions ( 9 , 10 ). In addition, there are several case reports describing the resolution of genital and non-genital difficult-to-treat recalcitrant warts after HPV vaccine administration ( 57 , 58 ).…”

Section: Hpv Vaccinationmentioning

confidence: 99%

“…Understanding that adult KT patients carry a high-risk for cancers, including HPV-related ones, and that the treatment for these diseases can negatively impact the graft viability and life expectancy , medical professionals need to get an early start with the most efficacious preventive strategies during childhood and adolescence ( 4 ). This article will delineate the most efficient primary prevention strategy, the HPV vaccination, which applied by pediatric professionals during childhood and adolescence has been proven to reduce the risk for HPV-associated malignancies for KT recipients during their adult life ( 9 , 10 ).…”

Section: Introductionmentioning

confidence: 99%

Human papillomavirus infection-related cancer risk for kidney transplant recipients during adult life can be reduced by vaccination during childhood and adolescence

Nailescu

Shew

2022

Front. Pediatr.

View full text Add to dashboard Cite

Malignancies are found between the first three reasons of mortality in pediatric and adult kidney transplant recipients, who overall have disproportionately higher rates of cancer compared to the general population, including human papillomavirus (HPV)-related genital, anal and oropharynx region cancers. Therefore, preventing HPV in this patient population is extremely important. HPV-vaccine was demonstrated to prevent HPV infection in individuals with intact immune systems. In addition, recent data reported less precancerous HPV lesions and cervical cancers with use of HPV vaccine. Since HPV is a sexually transmitted virus that is typically acquired shortly after the onset of sexual activity, it is best to administer the HPV vaccine immunization prior to the onset of sexual activity. This article reviews the epidemiology and pathophysiology of the HPV infection, as well as its role in the development of HPV-related pre-cancerous lesions and cancers in both general population and kidney transplant recipients. The focus is on the most effective primary prophylactic strategy, which is the HPV vaccination. The particularities of HPV vaccination strategies in kidney transplant recipients are compared to the general population. In addition, the article analyzes the various causes of suboptimal HPV immunization rates in kidney transplant candidates and recipients and discusses vaccination optimization strategies that can be applied during childhood and adolescence to reduce the burden of HPV-related disease states and cancer among adult kidney transplant recipients.

show abstract

“…The target of this vaccine is the viral capsid L1 of specific alpha HPV strains in mucosal types. Alpha-HPV and beta-HPV, however, show similarities in the immunogenic L1 and L2 capsid proteins [ 10 , 12 ]. In this regard, there is anecdotic evidence that HPV vaccination against alpha-genera has also resulted in the regression of cutaneous warts and cSCCs [ 13 , 14 , 15 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

HPV Vaccination in Immunosuppressed Patients with Established Skin Warts and Non-Melanoma Skin Cancer: A Single-Institutional Cohort Study

Bossart,

Daneluzzi,

Moor

et al. 2023

Vaccines

View full text Add to dashboard Cite

cSCC (cutaneous squamous cell carcinoma) and its precursors are a major cause of morbidity, especially in immunosuppressed patients, and are frequently associated with human papillomavirus (HPV) infections. The purpose of this study is to investigate the therapeutic potential of alpha-HPV vaccination for immunosuppressed patients with established cSCC and its precursors. In this retrospective study, all patients who received Gardasil-9®, a nonavalent HPV vaccine, as secondary prophylaxis were examined. Dermatologic interventions in both the pre- and post-vaccination periods were analyzed with zero-inflated Poisson regression and a proportional intensity model for repeated events with consideration of the clinically relevant cofactors. The hazard ratio for major dermatologic interventions was 0.27 (CI 0.14–0.51, p < 0.001) between pre- and post-Gardasil-9® intervention. Gardasil-9® vaccination showed good efficacy in reducing major dermatologic interventions even after correction of relevant cofactors and national COVID-19 caseloads during the observational period. Alpha-HPV vaccination may potentially cause a significant decrease in dermatologic interventions and overall mortality as well as healthcare costs in immunosuppressed patients with high skin tumor burden.

show abstract

Keratinocyte Carcinomas in Immunocompromised Patients Are Reduced After Administration of the Nonavalent Human Papillomavirus Vaccine

Cited by 6 publications

References 0 publications

Unveiling the Therapeutic Horizon: HPV Vaccines and Their Impact on Cutaneous Diseases—A Comprehensive Review

Unveiling the Therapeutic Horizon: HPV Vaccines and Their Impact on Cutaneous Diseases—A Comprehensive Review

Human papillomavirus infection-related cancer risk for kidney transplant recipients during adult life can be reduced by vaccination during childhood and adolescence

HPV Vaccination in Immunosuppressed Patients with Established Skin Warts and Non-Melanoma Skin Cancer: A Single-Institutional Cohort Study

Contact Info

Product

Resources

About